key: cord-0763486-wpdrkmvo
authors: Kwarteng, Alexander; Asiedu, Ebenezer; Sakyi, Samuel Amoah; Asiedu, Samuel Opoku
title: Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques
date: 2020-10-20
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2020.110914
sha: b22a88e43c86bfa85f735fa88c2b1b57387f10c5
doc_id: 763486
cord_uid: wpdrkmvo

The occurrence of the SARS-CoV2 infection has become a worldwide threat and the urgent need to discover therapeutic interventions remains paramount. The primary roles of the coronavirus nucleocapsid (N) protein are to interact with the viral genome and pack them into ribonucleoprotein complex. It also plays critical roles at many stages of the viral life cycle. Herein, we explore the N protein of SARS-CoV2 to identify promising epitope-based vaccine candidates and target the N-terminal domain of SARS-CoV2 N-protein for potential inhibitors using an integrative bioinformatics approach. We identified B-cell epitopes and T-cell epitopes that are non-toxic, non-allergenic, capable of inducing IFN-γ and structurally stable with high global population coverage of response. The (404)SKQLQQSMSSADS(416) and (92)RRIRGGDGKMKDL(104) sequences of N-protein were identified to induce B-cell immunity. We also identified (79)SSPDDQIGY(87) and (305)AQFAPSASAFFGMSR(319) as potential T-cell epitopes that form stable structures with human leucocyte antigens. We have also identified zidovudine triphosphate, an anti-HIV agent, as a potential inhibitor of the N-terminal domain of SARS-CoV2 N-protein based on docking and simulation analysis and should be considered for experimental validations. The findings of this study can help fast-track the discovery of therapeutic options to combat COVID-19.

The global incidence of the coronavirus disease 2019 (COVID- 19) has an estimated 20 million cases with over 740, 000 deaths as per current data available on 12 th August, 2020. The disease is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), the newest member of the family Coronaviridae. SARS-CoV2, SARS-CoV1 and Middle East Severe Acute Respiratory Syndrome Coronavirus (MERS-CoV) belong to the genus Betacoronavirus, thus, share particular genomic and proteomic similarities. It has been reported that SARS-CoV2 genome shares approximately 80% and 50% similarity with SARS-CoV1 and MERS-CoV, respectively [1, 2] . The structural proteins and enzymes of SARS-CoV2 are 90% homologous to those of SARS-CoV1 and MERS-CoV [3] . The clinical symptoms at the early stages of the disease include fever, fatigue and dry cough [4, 5] . Progression of the disease to a severe case is manifested as pneumonia and is usually accompanied by dyspnea and dry cough [6] . There are several complications associated with the SARS disease which include acute respiratory distress syndrome (ARDS), organ dysfunction, cardiac injury and systemic inflammation [4, 6] . The structural proteins of SARS-CoV2 namely; spike (S) glycoprotein, envelope (E), membrane (M) and nucleocapsid (N) proteins, play crucial roles during entry and survival of the virus in the host cell. The primary roles of the coronavirus N protein are to interacts with the viral genome and pack them into ribonucleoprotein (RNP) structure [7] [8] [9] .

Notwithstanding, the coronavirus N protein is multifunctional, having critical roles at many stages of the viral life cycle [10] . Notable among them are viral budding [10] , viral assembly [11] , regulation of host cell cycle [12] and regulation of viral mRNA replication [13, 14] . Considering the roles of the N protein and its high expression during viral infections, the N protein can be a promising target for drug and vaccine development. Targeting the N-protein provides opportunities to interfere with coronavirus assembly, transcription and replication. With the progression of the COVID-19 pandemic, search for pharmaceutical options are mainly driven by drug repurposing to reduce the drug discovery timeline [15] .

Considering the novelty and timing of COVID-19, research groups are beginning to understand aspects of the immunological response to the SARS-CoV2 to aid in the discovery of vaccines. The quest for safe and effective vaccines for COVID-19 has resulted in potential candidates with varying strategies and stages of developments.

According to reports by the World Health Organization (WHO) on 10 th August, 2020, 28 vaccine candidates have been registered and are currently in clinical evaluations and 139 candidates in pre-clinical evaluations [16] . Many of these candidates are sub-unit vaccines, as they provide a more logistically workable approach [17] and are capable of inducing both cellular and humoral responses [18] . Majority of the candidates in clinical evaluations target the S protein, considering its immuno-dominant nature.

However, there are reports that depict the N-protein as highly immunogenic with antigenic regions that are highly conserved across the coronaviruses [19] [20] [21] [22] [23] [24] . The conventional approaches for epitope-based vaccine identification are resourcedemanding, thus, designing epitope-based vaccines using bioinformatics offer a safer, inexpensive and more effective approach. In this paper, we integrate immunoinformatics, structure-based drug discovery and other computational methods to identify potential epitope-based vaccine and drug candidates that target the N-protein of SARS-CoV2. The results reveal potential N-protein epitopes that are highly immunogenic and elicit B-cell immunity, T-cell immunity, virus-specific antibody neutralization and natural killer cell-mediated immunity. The anti-HIV agent, zidovudine triphosphate was identified to potentially inhibit the N-terminal domain of SARS-CoV2 N-protein based on binding energy and simulation analysis.

The SARS-CoV2 nucleocapsid protein (N-protein) sequence was fetched from the NCBI protein database (https://www.ncbi.nlm.nih.gov/protein/QIC53221.1) and human leucocyte antigen (HLA) protein sequences were retrieved from the UniProt database (https://www.uniprot.org/). We used the SWISS-MODEL server (https://www.swissmodel.expasy.org/) to generate structures of the SARS-CoV2 Nprotein and the HLA proteins based on the co-ordinates of their respective homologous protein structures available at the protein data bank (https://www.rcsb.org/). J o u r n a l P r e -p r o o f

The linear and discontinuous B-cell epitopes were predicted using Bepipred 2.0 (http://www.cbs.dtu.dk/services/BepiPred/index.php) and ElliPro (http://tools.iedb.org/ellipro/), respectively. We used the interface provided by the IEBD web server (http://www.iedb.org/) for the predictions. Bepipred 2.0 uses a Random Forest regression algorithm to predict the probability that a residue of the antigenic protein is a member of an epitope [25] . The algorithm considers several properties of the antigenic residues including surface accessibility, hydrophobicity, secondary structure and polarity [25] . ElliPro combines three algorithms to predict discontinuous epitopes from a protein structure [26] . The first algorithm reconfigures the shape and surface of the query protein structure into an ellipsoid. Based on the ellipsoid shape, another algorithm estimates the protrusion index (PI) of each residue such that when a particular residue is seen outside the ellipsoid shape after 70% of the protein atoms are captured within the ellipsoid shape, then the PI of that residue is 0.7.

The last algorithm then determines the discontinuous epitopes by clustering neighboring residues based on a PI cut-off.

All T-cell epitopes were predicted using the IEBD web server 

The predicted epitopes were assessed based on toxicity, allergenicity and ability to induce IFN-γ. The toxicity of the peptides was predicted using a support vector machine-based algorithm developed by Gupta et al. [27] . We used AllerTop [28] to predict the antigenicity of each peptide. The ability of the epitopes to induce IFN-γ was J o u r n a l P r e -p r o o f predicted by IFNepitope [29] using the hybrid approach (motif and support vector machine).

Structural configurations of the selected epitopes were modeled using PEP-FOLD 3 [30] . The peptide models were then simulated using GROMACS 2020.3, following the protocol described in section 2.1.7. A 20 ns run was performed for each epitope and their root mean square deviation was computed using the GROMACS analysis tool.

The population coverage analysis tool available at IEBD (http://tools.iedb.org/population) was used to predict the percentage of individuals that would respond to the epitope(s) based on the HLA allele genotypic frequency within their ethnicities/areas. The frequency of HLA genotype within a population is provided by the Allele frequency database (http://www.allelefrequencies.net/).

The occurrence of the epitope sequence in other related coronaviruses was analyzed using Clustal omega (https://www.ebi.ac.uk/Tools/msa/clustalo/). The Nprotein of SARS-CoV1, MERS-CoV, Human coronaviruses (hCoV) OC43 and NL63

were considered for the homology analysis, noting the conservation of the epitope sequences across the related coronaviruses.

The best binding conformation of the epitope-HLA complex was determined with Cluspro 2.0 server [31] using the antibody model [32] . The Cluspro algorithm performs three steps in the protein-protein binding prediction [31] . The algorithm performs a rigid-body docking on a very large set of conformations using a Fast Fourier Transform (FFT)-dependent algorithm called PIPER [33, 34] . The docked conformations are the clustered based on root mean square deviation to select representative conformations of lowest energy [31] . The last computational step is energy minimization of the top conformations from step 2 using CHARMM force field [35] . The server is available at https://cluspro.bu.edu/home.php.

J o u r n a l P r e -p r o o f

The proteins were subjected to molecular dynamics simulations using GROMACS 2020.3 software suite [36] and CHARMM 2019 force filed. The structures were centered in a dodecahedron box, at least 1nm from the edges and solvated with spc216 water model. The system was electrostatically neutralized with 0.154 M NaCl. In order to get rid of inappropriate geometry and steric hindrances, energy minimization was performed on the system using the steepest descent algorithm for 10,000 steps with a maximum force threshold of 100 kJ/mol/nm. Van der-Waals interactions were treated with a single cut-off of 1.216 nm and long-range electrostatics were treated with the Particle-Mesh Ewald (PME) method with 0.16 FFT grid spacing and 4th order B-spline interpolation. Neighbor search was performed every 20 steps using the grid method with Verlet cut-off scheme. Protein and non-protein components of the system were independently coupled to v-rescale thermostat and an isotropic Berendsen algorithm for pressure coupling. The pressure was maintained by weak coupling to a reference pressure of 1 bar, with an isothermal compressibility of 4.6x10-5 bar -1 . The bond lengths within the protein were constrained using the LINCS algorithm. The system was subjected to a 400ps NVT and NPT equilibration, followed by 200 ns simulation using the leap-frog integrator. The trajectories were analyzed with built-in GROMACS commands and all graphic data were generated with the GRACE tool (http://plasmagate.weizmann.ac.il/Grace).

The immune response that would be elicited by the predicted epitopes was simulated using the C-ImmSim server (http://150.146.2.1/C-IMMSIM/index.php). C-ImmSim is based on the models developed by Celada-Seiden [37] [38] [39] and operates as an agent-based model that uses machine learning techniques to simulate the immune response towards a particular pathogen. The players of the immune system are represented as agents and the interactions between the agents are guided by set of rules that emanate from present understanding of immunological principles. These principles that are incorporated into the C-ImmSim algorithm include MHC restriction [40] , development of memory [41, 42] , clonal deletion theory [43] , processing and presentation of antigens [44] [45] [46] among others [47] . The algorithm does well to mimic the immune system as it simultaneously simulates immunological processes in the bone J o u r n a l P r e -p r o o f marrow (production of lymphoid and myeloid cells), the thymus (T-cell education), and the lymphatic system (immune surveillance) [47] . Three injections were given according to the dose series of 0, 2 and 6 months. All simulation parameters were set at default with time steps set at 1, 180, and 360 (each time step represent 8 hrs in reality).

In our structure-based drug discovery approach, we targeted the N-terminal domain of SARS-CoV2 N-protein because the domain is reported to have binding pockets for ribonucleoside 5'-monophosphates such as adenosine 5'-monophosphate (AMP) [8] .

We then retrieved an experimental structure of a related coronavirus in complex with AMP to aid in our analysis of the ligand's binding site in SARS-CoV2 N-protein. The receptor (SARS-CoV2 N-protein) was energy minimized for 10,000 steps using GROMACS 2020.3 and the low-energy structure was used for the analysis.

The AMP binding site in the N-terminal domain of SARS-CoV2 N-protein was elucidated through alignment of protein structures using PyMol 2.2 [48] . The algorithm performs sequence alignment followed by a structural superposition, and then cycle refinement in order to reject structural outliers found during the fitting. Since we were also interested in the all-atom root mean square deviation, we turned off the refinement process.

The N-terminal domain of the SARS-CoV2 nucleocapsid protein was targeted for potential inhibitors using a library of approved antiviral drugs. RMS cluster tolerance was set to 2.0Å. We clustered the docking conformations based on root mean square deviation and a tolerance of 2.0Å. The docked conformations were evaluated on the basis of binding energy and frequency of pose (cluster).

The energy terms governing the protein-ligand interactions were analyzed using 

The behavior of the protein-ligand complexes at the atomistic level was elucidated with molecular dynamics simulation using the method described in section 2. 

To determine the regions of SARS-CoV2 N-protein that may induce B-cell immunity, we predicted both linear and discontinuous B-cell epitopes using Bepipred 

We also predicted epitopes that may induce T-cell response against SARS-CoV2, based on ability to interact with specific HLA alleles. With over 3,400 predicted MHC class I restricted epitopes, consideration was given to those below a percentile rank of 0.5%. The percentile rank represents a randomly selected number of epitopes that are graded better than the candidate of interest, hence, a lower percentile rank is preferred.

As potential vaccine candidates, the predicted epitopes were profiled according to their toxicity, allergenicity and ability to induce IFN-γ. For the B-cell epitopes, preference was given to the non-toxins and non-allergen candidates with 8-11 amino acid residues. This resulted in 4 B-cell epitope candidates. The MHC-restricted epitopes that were predicted to be non-toxic, non-allergic and capable of inducing IFN-γ were considered for further analysis. This resulted in a total of 9 MHC-restricted epitopes.

The sequences of the selected epitopes after the evaluation process are shown in Table   1 .

J o u r n a l P r e -p r o o f

We performed molecular dynamics simulation for all the selected epitopes in order to inspect the stability of the peptides at the atomistic level. Prior to that, we built structural models for the epitopes using the PEP-FOLD3.5 server. The root mean square deviation (RMSD) from a 20 ns simulation was computed for each peptide and the results are shown in Table 1 . The RMSD tool compares the simulating model to the initial structural configuration (reference structure) and computes the deviation between the two structures. The epitopes with low RMSD values were selected for further analysis.

The aim of the population coverage analysis was to predict the percentage of a population that would respond to the epitopes, considering the frequency of HLA genotypic traits in the population. In general, a higher fraction of the population was predicted to respond to the MHCI-restricted epitope than the MHCII-restricted epitopes. Considering the global population, 75.47% of individuals would respond to the MHCI-restricted epitope while 56.23% of the individuals would respond to the MHCII-restricted epitopes ( Fig. 2A and B) . The lowest population coverage for the epitopes (both MHC I and II) was recorded in Central America and the highest recorded in East Asia (Fig. 2C) . The South African population did not respond very well to the MHCII-restricted epitopes, although there was a significant population coverage in other regions of Africa. The best coverage of the MHCI-restricted epitope was observed in Europe, South Asia, Africa, North and Southern America and the Oceania.

In order to check the cross-reactivity of the predicted epitopes across other related coronaviruses, a multiple sequence alignment study was performed using Clustal 

The interaction between the selected epitopes and their respective HLA proteins were studied using docking and simulation analysis. We predicted the binding conformations of the T-cell epitopes to HLA alleles using the Cluspro 2 server. The best binding conformations of the T-cell epitopes to their respective HLA alleles are shown in the epitope-HLA interactions. Although structural deviation was not significantly different for the MHCII-epitope complexes (Fig. 5B) , the HLA-DRB1*09:01-305 AQFAPSASAFFGMSR 319 complex seems to form the highest number of hydrogen bonds among the MHCII-restricted epitopes with ≈11 hydrogen bonds (Fig. 5D) . The results also suggest that the epitopes remained in close proximity to the HLA alleles with minimum distances ranging from 0.15 to 0.20 nm (Fig. 5E, F) .

We used the C-ImmSim server to simulate the immune response to the SARS- observed. The levels of these antibodies were low after the first injection but increased significantly following subsequent doses and this was accompanied by a concomitant reduction of antigen levels (Fig. 6A) . The major cytokines observed were IFN-γ and IL-2 (Fig. 6B) . Protection from B-cells and T-cells were notable along with development of immune memory. The immune memory developed by both B-cells and T-cells lasted for the period of the simulation (Fig. 6C, D) . Other immune cells,

including T-cytotoxic cells and natural killer cells, also elicited strong immune response to the antigen (Fig. 6E, F) .

The 7B ).

A library of 21 antiviral drugs with varying targets was used in our virtual screening analysis. The nomenclature, molecular weight, chemical structure and autodock score (estimated free energy of binding) are provided in Table 2 . Among the studied ligands, pleconaril (PLE), raltegravir (RAL) and zidovudine triphosphate (ZTP) recorded higher J o u r n a l P r e -p r o o f free energy of binding than AMP. The binding energy is referred to as 'autodock score' because the value, although efficient at discriminating suitable ligands from nonsuitable ones, does not accurately represent the binding affinity.

The molecular mechanics with Poisson-Boltzmann and surface area solvation (MM/PBSA) method of binding energy calculation is designed to be more accurate than the docking and scoring approach. For g_mmpbsa binding energy calculations, three energy terms are used namely molecular mechanics, polar solvation and non-polar solvation energies. The molecular mechanics potential energy includes energy of bonded and non-bonded interactions (Van-der Waals and electrostatic energies). The polar solvation term is calculated by solving the Poisson-Boltzmann equation [52] . The non-polar solvation term was calculated using the solvent accessible surface area (SASA) model and indicates repulsion and attraction between solvent and solute [52] .

The total binding energy of ZTP (-1312.837 kJ/mol) is significantly higher as compared to AMP (-108.234 kJ/mol) with major contributions from the electrostatic terms in both cases (Table 3) .

The 100 ns simulation revealed that the NTD-ZTP complex seems to be the most stable with RMSD of ≈ 0.3 nm while the NTD-AMP complex recorded RMSD of ≈ 0.35 nm (Fig. 8A) . Evolution of the total hydrogen bonds between the ligands and the NTD are shown in (Fig. 8B ) and ranged from 2 to 8 hydrogen bonds for NTD-AMP and NTD-ZTP complexes. The minimum distance between ligands and the protein (Fig.   8C ) ranged from 0.15 to 0.25 nm, suggesting close proximity especially for ZTP (≈ 0.15 nm). The compactness of the ZTP-NTD complex seems to be significantly low as compared to AMP-ZTP complex (see Fig. 8D ). Root Mean Square Fluctuations (RMSF) values for residues 91-102 (residues of the β-hairpin) were significantly higher upon binding of AMP than ZTP (Fig. 9A) . The flexibility of the β-hairpin residues was similar for the NTD and NTD-AMP complex. ZTP occupied the binding pocket of AMP and interacts with residues T49, S51, F53, R88, Y109, Y111 and R149 (Fig. 9B ). package of viral genome into a ribonucleoprotein complex [70, 71] . Kang et al. [72] solved the structure of the NTD of SARS-CoV2 N-protein (PDB ID: 6M3M) and

identified potential pockets for drug targeting. Considering the urgent need to contain the SARS-CoV2 infection, drug repurposing seems to be the best tool in the search for therapeutic options. Existing drugs for different targets such as chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have been re-oriented to target the SARS-CoV2 and several in-vitro and in-vivo studies are providing positive outcomes [73] [74] [75] . Based on MM/PBSA binding energy calculations and molecular dynamics simulation analysis, zidovudine triphosphate (ZTP) has higher affinity and interacts better with the NTD of N-protein than AMP. ZTP is an anti-HIV agent that targets the viral reverse transcriptase, thus interfering with the reverse transcription process [76] . Residual fluctuation analysis from the simulation studies revealed that upon binding of ZTP, the flexibility of the NTD β-hairpin (basic palm) residues significantly reduce. The impact could be detrimental for the NTD considering the roles of the flexible, positively charged β-hairpin. The β-hairpin has been proposed to be essential for RNA packaging by interacting with phosphate groups of the viral RNA [77] [78] [79] . This observation J o u r n a l P r e -p r o o f together with the high binding affinity depicts ZTP as a promising N-protein inhibitor and should be further validated by experimental studies.

We have explored the SARS-CoV2 N-protein for potential epitope-based vaccine candidates using immuno-informatics and identified an antiviral drug that binds to the 

Data is available upon request

The authors declare they have no competing interest. 

Return of the coronavirus: 2019-nCoV

Genome composition and divergence of the Novel Coronavirus (2019-nCoV) originating in China

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical, molecular and epidemiological characterization of the SARS-CoV2 virus and the Coronavirus disease 2019 (COVID-19), a comprehensive literature review, Diagnostic Microbiology and Infectious Disease

The Molecular Biology of Coronaviruses

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19

Molecular interactions in the assembly of coronaviruses

The Coronavirus Nucleocapsid Is a Multifunctional Protein

Coronavirus particle assembly: Primary structure requirements of the membrane protein

The severe acute respiratory syndrome coronavirus nucleocapsid protein is phosphorylated and localizes in the cytoplasm by 14-3-3-mediated translocation

Coronaviruses and toroviruses

Principles and Practice of Clinical Virology

Localization of mouse hepatitis virus nonstructural proteins and RNA synthesis indicates a role for late endosomes in viral replication

Drug repositioning an alternative for the treatment of coronavirus COVID-19

Draft of the landscape of COVID-19 candidate vaccines

Recent Advances in Subunit Vaccine Carriers

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

T cell responses to whole SARS coronavirus in humans

The trinity of COVID-19: immunity, inflammation and intervention

A serological assay to detect SARS-CoV-2 seroconversion in humans

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

BepiPred-2.0: improving sequencebased B-cell epitope prediction using conformational epitopes

ElliPro: a new structure-based tool for the prediction of antibody epitopes

Silico Approach for Predicting Toxicity of Peptides and Proteins

AllerTOP v.2-a server for in silico prediction of allergens

Designing of interferon-gamma inducing MHC class-II binders

PEP-FOLD3: fasterde novostructure prediction for linear peptides in solution and in complex

The ClusPro web server for protein-protein docking

Application of asymmetric statistical potentials to antibody-protein docking

PIPER: an FFT-based protein docking program with pairwise potentials

Molecular surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques

Charmm -a program for macromolecular energy, minimization, and dynamics calculations

GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

A computer model of cellular interactions in the immune system

A model for simulating cognate recognition and response in the immune system

Affinity maturation and hypermutation in a simulation of the humoral immune response

The major histocompatibility complex-restricted antigen receptor on T cells

The maturation of the immune response

The cellular basis of immunological memory

T cell selection in the thymus

Antigen processing at the molecular level

The nature and role of antigen processing in: in

Antigen-presenting function of the macrophage

Computational Immunology Meets Bioinformatics: The Use of Prediction Tools for Molecular Binding in the Simulation of the Immune System

Using PyMOL as a platform for computational drug design

UCSF Chimera?A visualization system for exploratory research and analysis

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

Cheatham 3rd, Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models

g_mmpbsa-A GROMACS Tool for High-Throughput MM-PBSA Calculations

Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors

T-Cell response profiling to biological threat agents including the SARS coronavirus

Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Molecular immune pathogenesis and diagnosis of COVID-19

Immunology of COVID-19: current state of the science

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Reinfection could not occur in SARS-CoV-2 infected rhesus macaques

Evaluation of antibody testing for SARS-CoV-2 using ELISA and lateral flow immunoassays

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patient, medRxiv

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Ribonucleocapsid formation of severe acute respiratory syndrome coronavirus through molecular action of the N-terminal domain of N protein

Amino acid residues critical for RNA-binding in the N-terminal domain of the nucleocapsid protein are essential determinants for the infectivity of coronavirus in cultured cells

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

Nelfi-navir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Approved antiviral drugs over the past 50 years

Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein

The nucleocapsid protein of coronavirus infectious bronchitis virus: Crystal structure of its N-terminal domain and multimerization properties

Amino acid residues critical for RNA-binding in the N-terminal domain of the nucleocapsid protein are essential determinants for the infectivity of coronavirus in cultured cells

Umifenovir ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)

Zalcitabine 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 211

Penciclovir 2-amino-9

Ganciclovir 2-amino-9

Acyclovir 2-amino-9

Valacyclovir 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3

5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl

J o u r n a l P r e -p r o o f

Tropical and Diseases SGP-III. We are also indebted to the staff of the Kwarteng Lab (KCCR) for their unflinching support in the preparation of this manuscript.

 Table 1 : Evaluation and characterization of epitopes. The predicted HLA allele that binds well to the MHC-restricted epitopes are also provided.

Peptide Length Toxicity Allergenicity RMSD (nm)